FindTrial
Sign In

Venlafaxine Extended Release (XR) (Oral Antidepressant)

DRUG5 trials

Sponsors

Janssen Research & Development, LLC

Conditions

Depressive Disorder, Treatment-ResistantTreatment-resistant Depression

Phase 3

A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression
CompletedNCT02417064
Janssen Research & Development, LLCTreatment-resistant Depression
Start: 2015-08-10End: 2018-02-20Updated: 2025-04-29
A Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression
CompletedNCT02418585
Janssen Research & Development, LLCTreatment-resistant Depression
Start: 2015-08-07End: 2017-11-06Updated: 2025-04-29
A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression
CompletedNCT02493868
Janssen Research & Development, LLCDepressive Disorder, Treatment-Resistant
Start: 2015-10-01End: 2018-02-16Updated: 2025-04-29
A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression
CompletedNCT02497287
Janssen Research & Development, LLCTreatment-resistant Depression
Start: 2015-09-30End: 2017-10-28Updated: 2025-04-29
A Study to Evaluate the Efficacy, Pharmacokinetics, Safety and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression
CompletedNCT03434041
Janssen Research & Development, LLCDepressive Disorder, Treatment-Resistant
Start: 2018-05-25End: 2021-04-13Updated: 2025-04-29

Related Papers

Addressing diversity gaps in esketamine clinical trials: a registry-based cross-sectional analysis of sex, race and ethnicity.
2026-02-12
Efficacy of intranasal esketamine versus rTMS for treatment-resistant depression: analysis of individual participant data from two clinical trials.
2025-10-30
Safety and efficacy with esketamine in treatment-resistant depression: long-term extension study
The International Journal of Neuropsychopharmacology2025-05-0412 citations
Estimating the benefit of esketamine nasal spray versus real-world treatment on patient-reported functional remission: results from the ICEBERG study
Frontiers in Psychiatry2024-10-073 citations
Effects of esketamine nasal spray on depressive symptom severity in adults with treatment-resistant depression and associations between the Montgomery–Åsberg Depression Rating Scale and the 9-item Patient Health Questionnaire
CNS Spectrums2024-04-014 citations
Indirect adjusted comparison of 6-month clinical outcomes between esketamine nasal spray and other real-world polypharmacy treatment strategies for treatment resistant depression: results from the ICEBERG study
Frontiers in Psychiatry2023-10-316 citations
ICEBERG study: an indirect adjusted comparison estimating the long-term benefit of esketamine nasal spray when compared with routine treatment of treatment resistant depression in general psychiatry
Frontiers in Psychiatry2023-10-314 citations
Efficacy and Safety of Esketamine Nasal Spray in Patients with Treatment-Resistant Depression Who Completed a Second Induction Period: Analysis of the Ongoing SUSTAIN-3 Study.
2023-08-0912 citations
Assessment of health-related quality of life and health status in patients with treatment-resistant depression treated with esketamine nasal spray plus an oral antidepressant.
2023-05-086 citations
Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Plus a Newly Initiated Oral Antidepressant in Adult Patients with Treatment-Resistant Depression: A Randomized, Double-Blind, Multicenter, Active-Controlled Study Conducted in China and USA.
2023-03-3124 citations
Predictors of response and remission in patients with treatment-resistant depression: A post hoc pooled analysis of two acute trials of esketamine nasal spray
Psychiatry Research2023-03-1516 citations
Adverse Events and Measurement of Dissociation After the First Dose of Esketamine in Patients With TRD
The International Journal of Neuropsychopharmacology2022-12-1411 citations
Intranasal esketamine effectively treats treatment-resistant depression in adults regardless of baseline irritability
Journal of Affective Disorders2022-10-2017 citations
Longitudinal Course of Adverse Events With Esketamine Nasal Spray
The Journal of Clinical Psychiatry2022-09-1614 citations
Evaluation of Individual Items of the Patient Health Questionnaire (PHQ-9) and Montgomery-Asberg Depression Rating Scale (MADRS) in Adults with Treatment-Resistant Depression Treated with Esketamine Nasal Spray Combined with a New Oral Antidepressant.
2022-04-209 citations
Relationship Between Dissociation and Antidepressant Effects of Esketamine Nasal Spray in Patients With Treatment-Resistant Depression
The International Journal of Neuropsychopharmacology2022-01-0552 citations
Efficacy and safety of esketamine nasal spray by sex in patients with treatment-resistant depression: findings from short-term randomized, controlled trials
Archives of Women s Mental Health2022-01-0131 citations
The effect of esketamine in patients with treatment-resistant depression with and without comorbid anxiety symptoms or disorder.
2021-07-2224 citations
Treatment Response With Esketamine Nasal Spray Plus an Oral Antidepressant in Patients With Treatment-Resistant Depression Without Evidence of Early Response
The Journal of Clinical Psychiatry2021-07-1621 citations
Effect of Esketamine Nasal Spray on Olfactory Function and Nasal Tolerability in Patients with Treatment-Resistant Depression: Results from Four Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Studies.
2021-07-0714 citations

13 more papers not shown